Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: effects on activity and drug response.
Genetics and drug interactions contribute to large interindividual variation in human CYP2D6 activity. Herein, we characterized propranolol inhibition in transgenic (TG) mice which express both mouse CYP2D and human CYP2D6 and in wildtype (WT) mice. Our purpose was to characterize propranolol as a CYP2D inhibitor in human and mouse, and to develop a method for in vivo manipulation of CYP2D6 enzyme activity which could be used to investigate the role of CYP2D6 in drug-induced behaviours. Dextromethorphan (DEX) metabolism to dextrorphan (DOR) was used to measure CYP2D activity and to characterize propranolol inhibition in vitro and in vivo. We also examined the impact of 24 h propranolol pre-treatment on serum levels of the CYP2D6 substrate haloperidol and haloperidol-induced catalepsy. TG hepatic DOR formation velocity was 3-fold higher than WT in vitro. Propranolol acted as a mechanism-based inhibitor (MBI), inactivating CYP2D in liver microsomes from TG and WT mice, and humans. Intraperitoneal 24 h pre-treatment of TG and WT mice with 20 mg·kg-1 propranolol significantly reduced DOR formation in vivo, and in liver tissue in vitro. Serum haloperidol levels and catalepsy were significantly increased. Propranolol was a potent MBI of DOR formation in liver microsomes from TG and WT mice, and humans; inhibition parameters in TG overlapped with WT mice and with humans. Manipulation of CYP2D with propranolol in vivo in TG and WT mice alters drug response, which will be useful for future investigation of the impact of variation in CYP2D6 on drug interactions and drug responses.